Biocomposites Invests in InfectoTest GmbH | Developers of a Bacterial-specific Point-of-care Test for Periprosthetic Joint infection

Michael Harris, Chief Executive Officer of Biocomposites, said: “Periprosthetic joint infection is a large and growing problem worldwide. Quickly and accurately pinpointing the bacteria that cause each infection is essential if patients are to receive the best care and maximise their chances of full recovery.